Skip to main content
OpenTrials
Completed

NCT Number: NCT01064245

Physiology of Cough in Asthma: Comparison of Sensory-Mechanical Responses to Mannitol and Methacholine Challenge Tests

Cough is a common, disruptive and at times disabling symptom which often prompts patients to seek medical attention. Determining the cause(s) of chronic cough can be challenging, and costly. Asthma and other airway disorders are among the most common causes of chronic cough; and cough can be the sole symptom of asthma. Little is known about why some patients with asthma primarily cough and do not develop the other symptoms of asthma such as shortness of breath or wheeze. Improved understanding of the reasons for these different manifestations may lead to new and more effective treatment strategies. We have notices differences in pressure measurements inside the chest in patients who mostly cough during induced bronchoconstriction, which might be part of the explanation for varying symptoms. This study will compare lung mechanical responses during methacholine and mannitol-induced induced airway narrowing between typical asthma, cough variant asthma (CVA) and an airway inflammatory disorder that is not asthma.The purpose of this research is to explore the pathophysiology and sensory-mechanics of cough in individuals with asthma, CVA and methacholine-induced cough but normal airway sensitivity using mannitol and high-dose methacholine bronchoprovocation testing.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with asthma or suspected CVA who have previously participated in or who have expressed interest in participating in studies will be invited to participate in the study. Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion, but medication use will be recorded and examined in the analysis.

Exclusion criteria

  • An exacerbation necessitating any alteration in medication, emergency department visit or hospitalizations within the previous 4 weeks;
  • Inability to perform acceptable quality spirometry;
  • Medical contraindications to methacholine challenge testing 35, including:
  • Severe airflow limitation (FEV1 <50% predicted or <1.0 L);
  • Heart attack or stroke in last 3 months;
  • Uncontrolled hypertension, systolic BP > 200 or diastolic BP > 100;
  • Known aortic aneurysm;
  • Moderate airflow limitation < 60% predicted or <1.5 L);
  • Inability to perform acceptable quality spirometry;
  • Current use of cholinesterase inhibitor medication (for myasthenia gravis); and
  • Pregnant or nursing mothers.
  • Smoking history in excess of 10 pack years;
  • Medical contraindications to mannitol challenge testing, including:
  • Aortic or cerebral aneurysm;
  • Uncontrolled hypertension; and
  • Myocardial infarction or a cerebral vascular accident in the previous six months).
  • Women who are pregnant or breastfeeding because the effects of a possible hyperresponsiveness reaction to mannitol in mothers and/or fetuses are unknown and many compounds are excreted in human milk therefore caution should be taken.

Treatment and study plan

high-dose methacholine challenge test

Drug

nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses

Other names: Provocholine

mannitol challenge test

Other

inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg

Other names: Aridol

Primary outcomes

  1. PD15 (15% fall in forced expiratory volume in one second (FEV1) from baseline during challenge test visits)

    Time frame: baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)

Secondary outcomes

  1. %ΔFEV1 (percentage change in forced expiratory volume in one second)

    Time frame: baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)

  2. Plateau response

    Time frame: baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)

  3. Dose-response slope

    Time frame: baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)

  4. Expiratory Flow Limitation (EFL)

    Time frame: baseline and several time points collected throughout test (high-dose methacholine challenge test or mannitol challenge test)

Sponsors and collaborators

Lead sponsor

Dr. Diane Lougheed

Other

Collaborators

  • Queen's University (William M Spear / Start Memorial Fund)
  • The Ontario Thoracic Society of the Ontario Lung Association

Registry information

Important dates

Study start
2010
Primary completion
2021
Study completion
2021
First posted
Feb 8, 2010
Registry last updated
Feb 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.